East Coast, USA-based biotech Skyhawk Therapeutics has announced the expansion of an existing collaboration with Biogen (Nasdaq: BIIB), and a new research deal with New Jersey’s Merck & Co (NYSE: MRK).
Skyhawk is working on the development of novel small molecule therapies using its proprietary SkySTAR (Skyhawk Small molecule Therapeutics for Alternative splicing of RNA) platform.
The firm has been highly active in partnering recently, the latest deals following closely on from several new collaborations, including a strategic collaboration with Japanese giant Takeda Pharmaceutical (TYO: 4502).
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze